Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...

Wall Street analysts forecast that Regeneron (REGN) will report quarterly earnings of $8.03 per share in its upcoming release, pointing to a year-over-year decline of 30.5%. It is anticipated that ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals has a 52 week low of $481.58 and a 52 week high of $1,211.20. The stock has a market capitalization of $52.67 billion, a P/E ratio of 12.74, a price-to-earnings-growth ...

Year to date, shares of EXEL have increased 22.4%. EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%.

Regeneron's first-quarter sales fell 4% year over year, while adjusted earnings per share dropped 14% lower. This is one of the most affordable large-cap biotech stocks today, but arguably for ...